ID 93 Vaccine
Title: A Phase Ib Randomized, Double-blind, Placebo-controlled, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of the ID93+GLA-SE vaccine in BCG-vaccinated Healthy Adults.
This is a double-blind, randomised placebo-controlled, dose escalation evaluation of two dose levels of the ID93 antigen administered intramuscularly in combination with two dose levels of the GLA-SE adjuvant. 66 healthy BCG-vaccinated, HIV-negative adults will be enrolled, first 12 QFT negative (not latently infected with M.tb) followed by QFT positive or negative participants . Three doses of study vaccine will be given at 0,1 and 4 months and follow up is for 6 months after final dose. ID93 contains Mtb antigens associated with both virulence and latency.
Principal Investigator: Michele Tameris
Partners: Aeras, Global TB Vaccine Foundation and IDRI